Bayer
NEWS
Mythic Therapeutics has roared out of the gate with a $103 million Series B financing round that will support “safer and smarter” next generation of antibody-drug conjugates (ADCs).
Bayer has high hopes of driving its prostate cancer drug into blockbuster status, meaning over $1 billion in annual sales. This week’s ARASENS trial results should help pave the road.
CStone forged a licensing agreement with Jiangsu Hengrui Pharmaceuticals that grants the company access to a monoclonal antibody aimed at multiple forms of cancer.
The first week of November was marked by numerous clinical trial announcements. Here’s a look.
Clade Therapeutics will use its funds to further its research and development on cancer treatments, while GRO Biosciences will focus on chronic diseases.
After guiding BlueRock Therapeutics and its potential Parkinson’s disease stem cell therapy into the clinic and to a $1 billion acquisition by Bayer, Emile Nuwaysir is taking on gene therapy startup Ensoma as CEO.
There was still some carryover from the European Society of Medical Oncology Congress 2021, but there was plenty of other clinical trial news last week. Here’s a look.
Three weeks after snagging approval in the UK, the U.S. FDA approved Samsung Bioepis and Biogen’s biosimilar drug. Byooviz is the first Lucentis copycat biologic to hit the market.
JOBS
IN THE PRESS